Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.00 Average PT from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $5.50.

CNTX has been the topic of several research analyst reports. D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. William Blair restated an "outperform" rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $4.00 price objective (down from $4.50) on shares of Context Therapeutics in a report on Thursday.

Context Therapeutics Stock Performance

NASDAQ:CNTX traded up $0.01 during midday trading on Thursday, reaching $0.66. The stock had a trading volume of 87,365 shares, compared to its average volume of 272,585. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.75. The firm's fifty day simple moving average is $0.72 and its 200-day simple moving average is $0.83.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). On average, sell-side analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Insiders Place Their Bets

In other Context Therapeutics news, CFO Jennifer Lynn Minai-Azary purchased 40,010 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average cost of $0.64 per share, with a total value of $25,606.40. Following the completion of the acquisition, the chief financial officer now directly owns 80,010 shares of the company's stock, valued at $51,206.40. This represents a 100.03% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martin A. Lehr acquired 100,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were bought at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the acquisition, the chief executive officer now owns 920,190 shares in the company, valued at approximately $644,133. The trade was a 12.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 160,010 shares of company stock valued at $107,206. 3.04% of the stock is currently owned by insiders.

Institutional Trading of Context Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $29,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $31,000. Shay Capital LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $52,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $94,000. Finally, Walleye Capital LLC boosted its stake in shares of Context Therapeutics by 51.7% in the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after purchasing an additional 56,651 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.